A PT-141 10mg vial label describes 10 milligrams of bremelanotide across the whole vial. It does not mean 10 mg is the amount for one use. A milligram is one-thousandth of a gram; here, it measures total drug mass.
If it is a compounded vial, that total will usually cover several uses. The concentration, prescribed amount, and pharmacy directions determine exactly how many. The big number on the front cannot answer that by itself.
What a PT-141 10mg vial actually tells you
The 10 mg figure answers one question: how much bremelanotide the labeled vial contains in total. It does not say how much liquid is in the vial or how much medication sits in each mark on a syringe.
Those details depend on concentration, meaning how many milligrams are present in each milliliter of liquid. Two vials can each contain 10 mg in total and still have different concentrations if their liquid volumes differ. The same syringe mark could then represent a different amount of drug in each vial.
That is why vial size and per-use amount have to stay separate. One describes the container. The other belongs to the prescription.
The brand comparison gives context, not a dose
The current Vyleesi label describes a single-dose autoinjector, a prefilled device that delivers one fixed amount. Each device contains 1.75 mg of bremelanotide in 0.3 milliliters (mL) of solution. It is used once and discarded.
That 1.75 mg amount was also used subcutaneously, meaning under the skin, in the two 24-week RECONNECT trials published in Obstetrics & Gynecology in 2019. The trials enrolled 1,267 premenopausal women with acquired, generalized hypoactive sexual desire disorder, or HSDD—low desire that causes distress and is not better explained by another condition, relationship problem, or drug.
In simple arithmetic, 10 mg is about 5.7 times 1.75 mg. That comparison explains why a 10 mg compounded vial can represent several uses. It does not turn the vial into a promise of six doses, and it does not make the brand amount the right amount for a compounded prescription.
Four numbers that are easy to confuse
A pharmacy label may put several small numbers close together. They do different jobs.
| Number | What it means | What it does not mean |
|---|---|---|
| 10 mg | Total drug mass in the vial | The amount for one use |
| mg/mL | Concentration of the prepared liquid | The syringe mark by itself |
| mL | Liquid volume | Drug mass without the concentration |
| Syringe units | Volume marks on that syringe | A fixed number of PT-141 milligrams |
A syringe unit is a measure of liquid volume, not a universal drug dose. Converting units to milligrams requires the exact concentration printed by the dispensing pharmacy. An ordinary online chart cannot see that label, so it cannot safely finish the calculation.
Nasal and injectable milligrams are not interchangeable
Route—how a medicine enters the body—matters too. Intranasal means delivered through the nose; it does not deliver the same fraction of a labeled amount as an injection under the skin.
A 2004 intranasal trial in men reported increasing blood exposure as nasal amounts rose, with erectile responses separating from placebo, an inactive comparison treatment, only at amounts above 7 mg. That figure belongs to an early nasal preparation and study population. It is not a conversion rule for a compounded injection.
The history behind that change in route belongs on the PT-141 nasal spray page. The practical point here is smaller: a 10 mg nasal bottle and a 10 mg injectable vial are not interchangeable just because the mass printed on them matches.
The same is true across different peptides. A 10 mg vial of PT-141 cannot be compared with a vial of kisspeptin as though milligrams measured equivalent strength. The molecules act through different pathways and have different human evidence. A prescriber starts with the clinical question, not the largest-looking vial number.
Fresh 2026 records make the label matter more
As of September 9, 2026, the day this article was written, two new primary records make the distinction especially concrete. An Analytical Methods paper published August 20, 2026 used forced degradation, a laboratory test that deliberately stresses a substance, and found bremelanotide especially susceptible to oxidation, damage caused by a reaction with oxygen. Breakdown was also observed under heat and light, and the researchers detected eight breakdown products. This was a lab study of the drug substance, not a test of patients or a particular dispensed vial.
Four days later, an FDA warning letter dated August 24, 2026 cited an online page offering a PT-141 10mg vial and called the PT-141 product as marketed an unapproved new drug, meaning that seller's product had no approved drug application. The letter did not report testing the vial's contents. Its action was about how the product was promoted and sold.
Together, the records show why total mass is only one line of a trustworthy label. Source, concentration, storage directions, lot tracking, and a responsible prescriber and pharmacy all matter too.
Compounded PT-141 and Vyleesi are different products
Through Promise, PT-141 is dispensed as a compounded medication, which is different from an FDA-approved product: the formulation offered here is not FDA-approved. Vyleesi is the approved brand for acquired, generalized HSDD in premenopausal women; its fixed autoinjector and narrow indication do not transfer automatically to a compounded vial.
A compounded medication is prepared by a pharmacy for an individual prescription. Its concentration and directions may differ from the brand device and from another pharmacy's preparation. That is why the pharmacy label, rather than the front-of-vial mass or a seller's calculator, controls the interpretation.
Regulatory status does not decide care by itself. A licensed provider may still prescribe a compounded formulation when medically appropriate; that decision is between the patient and the doctor.
What the pharmacy label should settle
A complete set of directions connects the numbers that a vial size leaves apart. It identifies the total strength, the concentration after preparation, the prescribed amount, the matching volume or syringe mark, the route, storage conditions, and the beyond-use date—the date after which the compounded preparation should not be used.
That last date matters because a multi-use vial can contain drug left over after several uses without remaining usable indefinitely. The 2026 stability paper does not supply a home-storage timetable. The dispensing pharmacy sets the storage and beyond-use instructions for the preparation it actually made.
When any two numbers seem to conflict, the uncertainty belongs with the pharmacy or prescriber before medication is measured. Guessing from the vial's total mass skips the one fact the calculation needs most: its concentration.
Where the dose and use questions belong
Vial size tells you what is in the container, not what a person should use. PT-141 dosage explains the study amounts and the brand label without turning them into a personal protocol. How to use PT-141 covers timing, administration, storage, and the questions that belong in a pharmacy conversation.
At Promise, a licensed provider reviews every request, and not everyone qualifies. The prescription and the pharmacy label—not “10 mg” by itself—are what turn a vial into an individual treatment plan.